<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340689</url>
  </required_header>
  <id_info>
    <org_study_id>13-006384</org_study_id>
    <nct_id>NCT02340689</nct_id>
  </id_info>
  <brief_title>Primary Hyperoxaluria Mutation Genotyping/Phenotyping</brief_title>
  <official_title>Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific mutations relating to hyperoxaluria will be determined via DNA analysis by the Mayo
      RKSC research staff.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During your study visit, we will draw one tube, about two teaspoons (1 to 1 Â½ teaspoons for
      children), of blood from your arm. White blood cells from the sample will be used as a source
      of DNA for genetic testing. We will use the DNA to try to identify mutations (changes) in one
      of the genes that can cause primary hyperoxaluria. This will be done by comparing it with the
      structure of these genes in normal individuals, patients with primary hyperoxaluria, and
      family members of primary hyperoxaluria patients. In family members of primary hyperoxaluria
      patients, a 24 hr urine test may also be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype markers of early symptomatic onset of primary hyperoxaluria</measure>
    <time_frame>5 years</time_frame>
    <description>Correlation of genotype with severity of disease as defined by age at onset of symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype markers of marked hyperoxaluria in patients with primary hyperoxaluria</measure>
    <time_frame>5 years</time_frame>
    <description>Correlation of genotype with severity of disease as defined by the level of urine oxalate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotype markers of early loss of kidney function in patients with primary hyperoxaluria.</measure>
    <time_frame>5 years</time_frame>
    <description>Correlation of genotype with age at kidney failure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Primary Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Genetic testing</arm_group_label>
    <description>Genetic Analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic Analysis</intervention_name>
    <description>We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.</description>
    <arm_group_label>Genetic testing</arm_group_label>
    <other_name>PH</other_name>
    <other_name>PH type 1</other_name>
    <other_name>Primary Hyperoxaluria</other_name>
    <other_name>Hyperoxlauria</other_name>
    <other_name>Primary Oxalosis</other_name>
    <other_name>PH type 2</other_name>
    <other_name>PH type 3</other_name>
    <other_name>Genetic testing for PH</other_name>
    <other_name>Genetic testing for Primary Hyperoxaluria</other_name>
    <other_name>Hereditary study for PH</other_name>
    <other_name>Hereditary study for Primary Hyperoxaluria</other_name>
    <other_name>AGXT</other_name>
    <other_name>GRHPR</other_name>
    <other_name>HOGA1</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA samples retained for potential future use, with consent of subjects only.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients with clinical characteristics suggesting of primary hyperoxaluria

          -  Family members of patients with clinical characteristics suggestive of primary
             hyperoxaluria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages birth to 99 years in whom clinical information is available from medical records

          -  Patients with a diagnosis of PH confirmed on previous genetic testing

          -  Patients with clinical suspicion of primary hyperoxaluria (elevated urine oxalate of
             greater than 0.8 mmol/1.73 m2/day (&gt;70 mg/1.73 m2/day), history of kidney stones,
             and/or nephrocalcinosis documented by medical history or imaging studies

          -  First or second degree family members of a patient with primary hyperoxaluria

        Exclusion Criteria:

          -  Stone formers who do not have confirmed PH and do not meet the inclusion criteria for
             clinical suspicion of primary hyperoxaluria

          -  Unwilling or unable to provide consent/assent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Milliner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Seide</last_name>
    <phone>507-255-0387</phone>
    <email>hyperoxaluriacenter@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyperoxlauria Center</last_name>
    <phone>800-270-4637</phone>
    <email>hyperoxaluriacenter@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Seide</last_name>
      <phone>507-255-0387</phone>
      <email>hyperoxaluriacenter@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hyperoxaluria Center</last_name>
      <phone>800-270-4637</phone>
      <email>hyperoxaluriacenter@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mayoclinic.org/nephrology-rst/hyperoxaluriacenter.html</url>
    <description>Mayo Clinic Hyperoxaluria Center</description>
  </link>
  <link>
    <url>http://www.mayoclinic.org/hyperoxaluria</url>
    <description>Mayo Clinic Hyperoxaluria and Oxalosis</description>
  </link>
  <link>
    <url>http://www.mayo.edu/research/clinical-trials/</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Lieske</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PH</keyword>
  <keyword>PH type 1</keyword>
  <keyword>Primary Hyperoxaluria</keyword>
  <keyword>Hyperoxaluria</keyword>
  <keyword>Primary Oxalosis</keyword>
  <keyword>PH type 2</keyword>
  <keyword>PH type 3</keyword>
  <keyword>Genetic testing for PH</keyword>
  <keyword>Genetic testing for Primary Hyperoxaluria</keyword>
  <keyword>Hereditary study for PH</keyword>
  <keyword>Hereditary study for Primary Hyperoxaluria</keyword>
  <keyword>AGXT</keyword>
  <keyword>GRHPR</keyword>
  <keyword>HOGA1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Using a limited data set, plans to share data in accordance with NIH funding expectations.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

